ADC Therapeutics Reports Impressive Results and Financial Updates for Q2 2025

ADC Therapeutics Releases Q2 2025 Financial Results

ADC Therapeutics SA (NYSE ADCT), known for its innovative antibody drug conjugates (ADCs), has announced its financial results for the second quarter ending June 30, 2025. The company has made substantial progress both operationally and financially, as outlined by CEO Ameet Mallik in the latest update.

Key Highlights from Q2 2025

1. Impressive Clinical Data: ADC Therapeutics has reported that its product ZYNLONTA®, when combined with glofitamab (COLUMVI®), resulted in a remarkable overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in patients treated during the LOTIS-7 study. This study sampled 30 efficacy evaluable individuals, reaffirming the potential effectiveness of this combination in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

2. Expansion of Clinical Trials: The company is currently progressing to expand the LOTIS-7 trial to include 100 patients with r/r DLBCL, which aims to provide more comprehensive data later this year. The anticipated timeline for sharing additional results is set for the latter half of 2025.

3. LOTIS-5 Trial Progress: The Phase 3 LOTIS-5 trial is also on schedule to meet its preset progression-free survival (PFS) event target by the end of 2025. Further updates will follow once data becomes available. This trial is focusing on the combination of ZYNLONTA with another approved treatment, rituximab, in patients who have undergone at least two lines of therapy.

4. Financial Milestones: ADC Therapeutics completed a private placement financing effort raising $100 million, thereby extending its cash runway into 2028. This funding is aimed at supporting the ongoing clinical development and commercialization activities of ZYNLONTA.

Financial Performance Overview

For Q2 2025, ADC Therapeutics reported net product revenues of $18.1 million, an increase from $17.0 million in Q2 2024. Over the first half of the year, total revenues reached $41.9 million, compared to $35.5 million over the same period last year.

Research and Development Expenses: R&D expenses were recorded at $30.1 million for the quarter, up from $24.3 million year-on-year. This rise is attributed primarily to clinical trial activities surrounding LOTIS-5 and LOTIS-7.

Net Loss: The company reported a net loss of $56.6 million, which equates to $0.50 per basic and diluted share, compared to a net loss of $36.5 million (or $0.38 per share) in Q2 2024. Adjusted net loss metrics were also shared, reflecting an adjusted net loss of $28.7 million in Q2 2025, marking an increase compared to $24.4 million of adjusted net loss reported for the same quarter in 2024.

Future Strategic Direction

As ADC Therapeutics heads into the second part of 2025, the focus remains intensified on expanding the applications of ZYNLONTA across various treatment lines in DLBCL and indolent lymphomas. The strategic restructuring plan announced earlier this year has led to the discontinuation of certain preclinical projects in solid tumors and will involve reducing the workforce by approximately 30%, with completion expected by the end of September 2025.

The management emphasizes its commitment to prudent execution of the current strategy, which is expected to unlock substantially larger therapeutic opportunities for ZYNLONTA in the near future. Clinical data presentations are anticipated to continue generating excitement and further support regulatory engagements in the year ahead.

With strong financial backing and promising clinical outcomes, ADC Therapeutics is positioned for notable growth and advancement in the biopharmaceutical sector. The company's continuous efforts in research and development, particularly concerning ADCs like ZYNLONTA, suggest an exciting path forward in improving outcomes in patients with serious hematological disorders.